NO20056089L - Glykosaminoglykaner for behandling av emosjonelle dysfunksjoner - Google Patents

Glykosaminoglykaner for behandling av emosjonelle dysfunksjoner

Info

Publication number
NO20056089L
NO20056089L NO20056089A NO20056089A NO20056089L NO 20056089 L NO20056089 L NO 20056089L NO 20056089 A NO20056089 A NO 20056089A NO 20056089 A NO20056089 A NO 20056089A NO 20056089 L NO20056089 L NO 20056089L
Authority
NO
Norway
Prior art keywords
treatment
glycosaminoglycans
disorders
emotional
emotional dysfunction
Prior art date
Application number
NO20056089A
Other languages
English (en)
Inventor
Luigi De Ambrosi
Israel Hanin
Jawed Fareed
John Lee
Stanley Lorens
Ronald F Mervis
Original Assignee
Cornelli Umberto
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cornelli Umberto filed Critical Cornelli Umberto
Publication of NO20056089L publication Critical patent/NO20056089L/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Psychiatry (AREA)
  • Epidemiology (AREA)
  • Pain & Pain Management (AREA)
  • Anesthesiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Polysaccharides And Polysaccharide Derivatives (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Plant Substances (AREA)

Abstract

Den foreliggende oppfinnelse angår anvendelsen av glykosaminoglykanfraksjoner med en gjennomsnittelig molekylvekt på 2400 ((200) D for fremstillingen av farmasøytiske preparater egnet for behandlingen av emosjonelle dysfunksjoner, spesielt depressive lidelser, angstsykdommer, angstnevroser, sinnsbevegelser, forvirring.
NO20056089A 2003-05-21 2005-12-21 Glykosaminoglykaner for behandling av emosjonelle dysfunksjoner NO20056089L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IT001023A ITMI20031023A1 (it) 2003-05-21 2003-05-21 Glicosaminoglicani aventi peso molecolare medio 2400 d atti al trattamento delle disfunzioni emozionali.
PCT/EP2004/050860 WO2004103381A1 (en) 2003-05-21 2004-05-19 Glycosaminoglycans for treatment emotional dysfunctions

Publications (1)

Publication Number Publication Date
NO20056089L true NO20056089L (no) 2006-02-09

Family

ID=30131059

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20056089A NO20056089L (no) 2003-05-21 2005-12-21 Glykosaminoglykaner for behandling av emosjonelle dysfunksjoner

Country Status (21)

Country Link
US (1) US7812005B2 (no)
EP (1) EP1631298B8 (no)
JP (1) JP4757197B2 (no)
KR (1) KR20060025142A (no)
CN (1) CN100377717C (no)
AT (1) ATE373480T1 (no)
AU (1) AU2004241748B2 (no)
CA (1) CA2526201A1 (no)
DE (1) DE602004009068T2 (no)
DK (1) DK1631298T3 (no)
ES (1) ES2294507T3 (no)
HK (1) HK1084023A1 (no)
IL (1) IL171981A (no)
IT (1) ITMI20031023A1 (no)
NO (1) NO20056089L (no)
NZ (1) NZ544238A (no)
PL (1) PL1631298T3 (no)
PT (1) PT1631298E (no)
RU (1) RU2353371C2 (no)
WO (1) WO2004103381A1 (no)
ZA (1) ZA200510132B (no)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101584704B (zh) * 2008-05-23 2010-12-15 鲁南制药集团股份有限公司 肝素、低分子肝素可药用盐或其衍生物的医药用途
CN107760713B (zh) * 2016-08-23 2020-05-05 中国科学院上海药物研究所 一种非人哺乳动物神经精神疾病动物模型的建立方法及其用途
CN112438991B (zh) * 2019-08-29 2024-03-15 鲁南制药集团股份有限公司 肝素、或其衍生物、或其可药用盐的医药用途

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4351938A (en) * 1980-05-19 1982-09-28 Riker Laboratories, Inc. Anticoagulant substance
US4916219A (en) * 1985-03-28 1990-04-10 University Of Iowa Research Foundation Oligosaccharide heparin fragments as inhibitors of complement cascade
IT1205042B (it) 1987-05-28 1989-03-10 Crinos Industria Farmaco Composizione farmaceutica ad attivita' terapeutica per il trattamento della demenza senile di tipo alzheimer
US5605938A (en) 1991-05-31 1997-02-25 Gliatech, Inc. Methods and compositions for inhibition of cell invasion and fibrosis using dextran sulfate
FR2763848B1 (fr) * 1997-05-28 2000-01-28 Rhone Poulenc Rorer Sa Utilisation des heparines de bas poids moleculaire pour la prevention et le traitement du trauma du systeme nerveux central
FR2763849B1 (fr) * 1997-05-28 2000-09-15 Rhone Poulenc Rorer Sa Utilisation des heparines de bas poids moleculaire pour la prevention et le traitement des oedemes cerebraux
JP4412756B2 (ja) * 1998-02-26 2010-02-10 生化学工業株式会社 新規多糖誘導体、その製造法及びそれを有効成分とする医薬組成物
IT1312107B1 (it) * 1999-05-14 2002-04-04 Umberto Cornelli Glicosaminoglicani aventi peso molecolare medio di 2400 d atti altrattamento della demenza senile

Also Published As

Publication number Publication date
EP1631298A1 (en) 2006-03-08
IL171981A (en) 2010-04-15
PT1631298E (pt) 2007-12-31
DE602004009068D1 (de) 2007-10-31
AU2004241748A1 (en) 2004-12-02
AU2004241748B2 (en) 2010-05-13
JP2006528670A (ja) 2006-12-21
WO2004103381A1 (en) 2004-12-02
KR20060025142A (ko) 2006-03-20
EP1631298B8 (en) 2008-12-24
IL171981A0 (en) 2006-04-10
EP1631298B1 (en) 2007-09-19
US7812005B2 (en) 2010-10-12
CN100377717C (zh) 2008-04-02
JP4757197B2 (ja) 2011-08-24
DK1631298T3 (da) 2008-01-28
RU2353371C2 (ru) 2009-04-27
DE602004009068T2 (de) 2008-06-19
HK1084023A1 (en) 2006-07-21
ATE373480T1 (de) 2007-10-15
ITMI20031023A1 (it) 2004-11-22
PL1631298T3 (pl) 2008-04-30
ITMI20031023A0 (it) 2003-05-21
CA2526201A1 (en) 2004-12-02
RU2005138517A (ru) 2006-08-27
US20060205690A1 (en) 2006-09-14
CN1791416A (zh) 2006-06-21
NZ544238A (en) 2008-08-29
ES2294507T3 (es) 2008-04-01
ZA200510132B (en) 2006-08-30

Similar Documents

Publication Publication Date Title
MXPA05009595A (es) Compuestos 7-amino-isoindolilo y sus usos farmaceuticos.
TW200612905A (en) Novel sulfamate and sulfamide derivatives useful for the treatment of epilepsy and related disorders
MY147767A (en) Novel sulfamate and sulfamide derivatives useful for the treatment of epilepsy and related disorders
CO5660287A2 (es) Derivados de tetrahidrocarbazol y su uso farmaceutico
CY1118179T1 (el) Φαρμακευτικη συνθεση
HK1096392A1 (en) Substituted heterocycles
ATE540948T1 (de) Pyrrolopyridine als proteinkinasehemmer
ATE402929T1 (de) Pyrazinverbindungen als inhibitoren des transforming growth factor (tgf)
HK1092467A1 (en) N-alkyl-hydroxamic acid-isoindolyl compounds and their pharmaceutical uses n-
ATE449081T1 (de) Fluoralkoxy-substituierte 1, 3-dihydro-isoindolyl-verbindungen und ihre pharmazeutischen verwendungen
MXPA05009304A (es) Derivados de indol utiles para el tratamiento de enfermedades.
ZA200701661B (en) Isoindoline compounds and methods of making and using the same
GEP20084452B (en) Sulfonamide derivatives for the treatment of diseases
SE0301653D0 (sv) Novel compounds
IL188942A0 (en) Benzimidazole derivatives and pharmaceutical compositions containing the same
IL179206A0 (en) Pyrrolylpyrimidine derivatives and pharmaceutical compositions containing the same
ATE388708T1 (de) Piperazinderivate und anwendungsverfahren
NO20056089L (no) Glykosaminoglykaner for behandling av emosjonelle dysfunksjoner
ATE373644T1 (de) N-substituierte 3-hydroxy-4-pyridinone und diese enthaltende pharmazeutika
EP1802297A4 (en) COMPOSITIONS AND METHODS FOR TREATING DISEASES CAUSED BY YERSINIA SPP INFECTION
TW200504051A (en) Novel acridine derivatives and their use as medicaments
UY27372A1 (es) Derivados de bencimidazol 1-aril-2-n, s u o-sustituidos, su uso para la obtención de medicamentos y preparados farmacéuticos que contienen estos derivados
EA200500865A1 (ru) Синергетическая комбинация, включающая рофлумиласт и r,r-формотерол
FR2860234B1 (fr) Nouveaux derives 666 du thioxylose
SE0100295D0 (sv) New compounds

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application